These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 37344677)
1. A chance to cut is a chance to cure: complete resection of an atypical neurofibroma prevents further progression to malignancy. Vaassen P; Feldkamp A; Scholz M; Blau T; Dürr NR; Rosenbaum T Childs Nerv Syst; 2023 Nov; 39(11):3301-3304. PubMed ID: 37344677 [TBL] [Abstract][Full Text] [Related]
2. Plexiform neurofibromas. Korf BR Am J Med Genet; 1999 Mar; 89(1):31-7. PubMed ID: 10469434 [TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Mek Inhibitors in the Treatment of Plexiform Neurofibromas: A Retrospective Study. Cacchione A; Fabozzi F; Carai A; Colafati GS; Baldo GD; Rossi S; Diana M; Megaro G; Milano GM; Macchiaiolo M; Crocoli A; De Ioris MA; Boccuto L; Secco DE; Zama M; Agolini E; Tomà P; Mastronuzzi A Cancer Control; 2023; 30():10732748221144930. PubMed ID: 36598023 [TBL] [Abstract][Full Text] [Related]
4. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials. Acar S; Armstrong AE; Hirbe AC Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916 [TBL] [Abstract][Full Text] [Related]
5. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. Gross AM; Glassberg B; Wolters PL; Dombi E; Baldwin A; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Whitcomb P; Paul SM; Steinberg SM; Venzon DJ; Martin S; Carbonell A; Heisey K; Therrien J; Kapustina O; Dufek A; Derdak J; Smith MA; Widemann BC Neuro Oncol; 2022 Nov; 24(11):1978-1988. PubMed ID: 35467749 [TBL] [Abstract][Full Text] [Related]
6. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. Waggoner DJ; Towbin J; Gottesman G; Gutmann DH Am J Med Genet; 2000 May; 92(2):132-5. PubMed ID: 10797438 [TBL] [Abstract][Full Text] [Related]
7. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas. Anderson MK; Johnson M; Thornburg L; Halford Z Ann Pharmacother; 2022 Jun; 56(6):716-726. PubMed ID: 34541874 [TBL] [Abstract][Full Text] [Related]
8. Intra-parotid facial nerve multiple plexiform neurofibroma in patient with NF1. Fadda MT; Verdino G; Mustazza MC; Bartoli D; Iannetti G Int J Pediatr Otorhinolaryngol; 2008 May; 72(5):553-7. PubMed ID: 18329107 [TBL] [Abstract][Full Text] [Related]
10. Management issues in massive pediatric facial plexiform neurofibroma with neurofibromatosis type 1. Wise JB; Patel SG; Shah JP Head Neck; 2002 Feb; 24(2):207-11. PubMed ID: 11891951 [TBL] [Abstract][Full Text] [Related]
11. Resection of plexiform neurofibromas in children with neurofibromatosis type 1. Canavese F; Krajbich JI J Pediatr Orthop; 2011; 31(3):303-11. PubMed ID: 21415691 [TBL] [Abstract][Full Text] [Related]
12. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781 [TBL] [Abstract][Full Text] [Related]
14. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT. Gross AM; Achée C; Hart SE; Brewer L; Baldwin A; Wolters PL; Widemann BC; Future Oncol; 2024 May; 20(14):877-890. PubMed ID: 38869947 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma. Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222 [No Abstract] [Full Text] [Related]
16. Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening. Kraniak JM; Chalasani A; Wallace MR; Mattingly RR Exp Neurol; 2018 Jan; 299(Pt B):289-298. PubMed ID: 29055717 [TBL] [Abstract][Full Text] [Related]
17. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation. Tsai LL; Drubach L; Fahey F; Irons M; Voss S; Ullrich NJ J Neurooncol; 2012 Jul; 108(3):469-75. PubMed ID: 22407214 [TBL] [Abstract][Full Text] [Related]
18. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. Espírito Santo V; Passos J; Nzwalo H; Carvalho I; Santos F; Martins C; Salgado L; Silva CE; Vinhais S; Vilares M; Salgado D; Nunes S J Neurooncol; 2020 Apr; 147(2):459-463. PubMed ID: 32108293 [TBL] [Abstract][Full Text] [Related]
20. Giant gluteal and vesical plexiform neurofibromas in a patient with neurofibromatosis type 1: a case report. Sassi I; Bouida MA; Hasnaoui A; Zemni I; Ben Dhieb T J Med Case Rep; 2024 Jan; 18(1):15. PubMed ID: 38216958 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]